Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Jan;36(1):167–171. doi: 10.1128/aac.36.1.167

Synergistic effects of romurtide and cefmenoxime against experimental Klebsiella pneumonia in mice.

O Tatara 1, C Nakahama 1, Y Niki 1
PMCID: PMC189247  PMID: 1590684

Abstract

We investigated the synergistic effects of romurtide (MDP-Lys [L18]) and cefmenoxime (CMX) in the treatment of experimental Klebsiella pneumonia in mice. Mice were infected with 1 x 10(4) CFU of Klebsiella pneumoniae by inhalation of aerosol bacterial suspension. About 90% of untreated animals died within a week; however, the mortality rate of animals treated with CMX alone at a dose of 40 mg/kg/day was 60% at 7 days after the infection. When one or two doses of L18 were administered before or after the infection concomitantly with CMX, a remarkable improvement in the survival rate was observed. There was no significant improvement in the survival rate of animals treated with L18 alone before or after infection. Histopathological sections of the lungs of mice treated with CMX and L18 showed slower progression of infection than those of mice treated with CMX alone. Significant differences were also found in quantitative cultures of viable bacteria in the lungs 1 to 4 days after the infection. Although viable bacterial counts in the lungs of the control and CMX-treated groups showed a rapid increase 24 to 48 h after the infection, they remained lower than the initial counts (x 10(4)) in the lungs of mice treated with combination regimens. From these results, it can be concluded that L18 is a useful biological response modifier in the treatment of acute pulmonary bacterial infections.

Full text

PDF
167

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adam A., Ciorbaru R., Ellouz F., Petit J. F., Lederer E. Adjuvant activity of monomeric bacterial cell wall peptidoglycans. Biochem Biophys Res Commun. 1974 Feb 4;56(3):561–567. doi: 10.1016/0006-291x(74)90640-8. [DOI] [PubMed] [Google Scholar]
  2. Adam A., Devys M., Souvannavong V., Lefrancier P., Choay J., Lederer E. Correlation of structure and adjuvant activity of N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP), its derivatives and analogues. Anti-adjuvant and competition properties of stereoisomers. Biochem Biophys Res Commun. 1976 Sep 7;72(1):339–346. doi: 10.1016/0006-291x(76)90999-2. [DOI] [PubMed] [Google Scholar]
  3. Akasaki M. Activation of immune responses by muroctasin. Arzneimittelforschung. 1988 Jul;38(7A):976–977. [PubMed] [Google Scholar]
  4. Azuma I., Sugimura K., Taniyama T., Yamawaki M., Yamamura Y. Adjuvant activity of mycobacterial fractions: adjuvant activity of synthetic N-acetylmuramyl-dipeptide and the related compounds. Infect Immun. 1976 Jul;14(1):18–27. doi: 10.1128/iai.14.1.18-27.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Azuma I., Sugimura K., Yamawaki M., Uemiya M., Kusumoto S., Okada S., Shiba T., Yamamura Y. Adjuvant activity of synthetic 6-O-"mycoloyl"-N-acetylmuramyl-L-alanyl-D-isoglutamine and related compounds. Infect Immun. 1978 Jun;20(3):600–607. doi: 10.1128/iai.20.3.600-607.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chedid L., Parant M., Parant F., Lefrancher P., Choay J., Lederer E. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A. 1977 May;74(5):2089–2093. doi: 10.1073/pnas.74.5.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1974 Aug 19;59(4):1317–1325. doi: 10.1016/0006-291x(74)90458-6. [DOI] [PubMed] [Google Scholar]
  8. Endo N. In vitro and in vivo augmentation by muroctasin of the production of the third component of complement by murine macrophages. Arzneimittelforschung. 1988 Jul;38(7A):993–996. [PubMed] [Google Scholar]
  9. Endo N., Okuda T., Osada Y., Zen-Yoji H. Stimulation of complement production in mice by N alpha-(N-acetylmuramyl-L-alanyl-D-isoglutamine)-N epsilon-stearoyl-L-lysine. Infect Immun. 1983 Nov;42(2):618–622. doi: 10.1128/iai.42.2.618-622.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Endo N., Okuda T., Osada Y., Zen-Yoji H. Stimulation of plasma fibronectin production in mice by muroctasin. Arzneimittelforschung. 1988 Jul;38(7A):997–998. [PubMed] [Google Scholar]
  11. Kireszenbaum F., Ferraresi R. W. Enhancement of host resistance against Trypanosoma cruzi infection by the immunoregulatory agent muramyl dipeptide. Infect Immun. 1979 Jul;25(1):273–278. doi: 10.1128/iai.25.1.273-278.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Krahenbuhl J. L., Sharma S. D., Ferraresi R. W., Remington J. S. Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice. Infect Immun. 1981 Feb;31(2):716–722. doi: 10.1128/iai.31.2.716-722.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Matsumoto K., Ogawa H., Kusama T., Nagase O., Sawaki N., Inage M., Kusumoto S., Shiba T., Azuma I. Stimulation of nonspecific resistance to infection induced by 6-O-acyl muramyl dipeptide analogs in mice. Infect Immun. 1981 May;32(2):748–758. doi: 10.1128/iai.32.2.748-758.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Matsumoto K., Otani T., Une T., Osada Y., Ogawa H., Azuma I. Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the gamma-carboxyl group and evaluation of N alpha-muramyl dipeptide-N epsilon-stearoyllysine. Infect Immun. 1983 Mar;39(3):1029–1040. doi: 10.1128/iai.39.3.1029-1040.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Nakajima R., Ishida Y., Yamaguchi F., Otani T., Ono Y., Nomura M., Une T., Osada Y. Beneficial effect of muroctasin on experimental leukopenia induced by cyclophosphamide or irradiation in mice. Arzneimittelforschung. 1988 Jul;38(7A):986–992. [PubMed] [Google Scholar]
  16. Ono Y., Iwasaki T., Furuhama K., Onodera T. Acute toxicity of muroctasin in mice, rats and dogs. Arzneimittelforschung. 1988 Jul;38(7A):1022–1024. [PubMed] [Google Scholar]
  17. Osada Y., Mitsuyama M., Matsumoto K., Une T., Otani T., Ogawa H., Nomoto K. Stimulation of resistance of immunocompromised mice by a muramyl dipeptide analog. Infect Immun. 1982 Sep;37(3):1285–1288. doi: 10.1128/iai.37.3.1285-1288.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Osada Y., Mitsuyama M., Une T., Matsumoto K., Otani T., Satoh M., Ogawa H., Nomoto K. Effect of L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections. Infect Immun. 1982 Jul;37(1):292–300. doi: 10.1128/iai.37.1.292-300.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Osada Y., Ohtani T., Une T., Ogawa H., Nomoto K. Enhancement of non-specific resistance to Pseudomonas pneumonia by a synthetic derivative of muramoyl dipeptide in immunosuppressed guinea pigs. J Gen Microbiol. 1982 Oct;128(10):2361–2370. doi: 10.1099/00221287-128-10-2361. [DOI] [PubMed] [Google Scholar]
  20. Osada Y., Otani T., Sato M., Une T., Matsumoto K., Ogawa H. Polymorphonuclear leukocyte activation by a synthetic muramyl dipeptide analog. Infect Immun. 1982 Dec;38(3):848–854. doi: 10.1128/iai.38.3.848-854.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Otani T., Katami K., Une T., Osada Y., Ogawa H. Restoration by MDP-Lys (L18) of resistance to Pseudomonas pneumonia in immunosuppressed guinea pigs. Microbiol Immunol. 1984;28(9):1077–1082. doi: 10.1111/j.1348-0421.1984.tb00764.x. [DOI] [PubMed] [Google Scholar]
  22. Otani T., Une T., Osada Y. Stimulation of non-specific resistance to infection by muroctasin. Arzneimittelforschung. 1988 Jul;38(7A):969–976. [PubMed] [Google Scholar]
  23. Parant M., Parant F., Chedid L. Enhancement of the neonate's nonspecific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3395–3399. doi: 10.1073/pnas.75.7.3395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Tsubura E., Nomura T., Niitani H., Osamura S., Okawa T., Tanaka M., Ota K., Nishikawa H., Masaoka T., Fukuoka M. Restorative activity of muroctasin on leukopenia associated with anticancer treatment. Arzneimittelforschung. 1988 Jul;38(7A):1070–1074. [PubMed] [Google Scholar]
  25. Yamaguchi F., Akahane K., Takashi T., Tsukada W. Production of colony-stimulating factor from macrophages by muroctasin. Arzneimittelforschung. 1988 Jul;38(7A):983–986. [PubMed] [Google Scholar]
  26. Yamaguchi F., Akasaki M., Tsukada W. Induction of colony-stimulating factor and stimulation of stem cell proliferation by injection of muroctasin. Arzneimittelforschung. 1988 Jul;38(7A):980–983. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES